On dialysis after a heart attack or stroke: starting a statin was linked to longer survival

Design

Registry-based target-trial emulation with inverse probability weighting

Population

5,534 French adults on dialysis after an atherosclerotic cardiovascular event

Primary outcome

All-cause mortality

Effect

Risk difference −6.2% at 4 years (95% CI −10.2 to −2.2); survival gain 135 days at 10 years

Randomised trials of statins in dialysis have been neutral, but they mixed primary and secondary prevention and excluded people with recent cardiovascular events. This French study linked the national dialysis registry to health insurance data from 2010 to 2023 and emulated a trial in 5,534 dialysis patients (median age 75) who had an atherosclerotic cardiovascular event, comparing those who started a statin with those who did not, weighted for baseline differences.

Statin initiation was associated with lower all-cause mortality. The largest absolute difference was at four years (risk difference −6.2%, 95% CI −10.2 to −2.2; relative risk 0.88). Mean survival gain was 69 days at five years and 135 days at ten. Hospital admissions for rhabdomyolysis or toxic hepatitis did not differ.

This is observational, and people who start statins may differ in ways the weighting cannot capture. Even so, it addresses exactly the group the trials left out. KDIGO currently suggests not starting statins in people on dialysis, and one observational study does not change that guidance. It does support a case-by-case discussion for a dialysis patient after a myocardial infarction or ischaemic stroke, rather than assuming a statin is pointless.

• Discuss statins case by case with dialysis patients after an atherosclerotic cardiovascular event.
• Do not assume statins are futile in dialysis because trials in mixed populations were neutral.
• Expect a modest benefit — months of life over years — and discuss it with the patient.
• Muscle and liver toxicity were not increased, but review interacting drugs.
• Continue statins already started before dialysis, as current guidance allows.

Why it matters

Dialysis patients after a cardiovascular event are often left off statins on the strength of trials that excluded them.

Don't overread it

This is observational; residual confounding could explain part of the survival difference.

The statistics, in plain English

Restricted mean survival time compares average time alive over a fixed period. A gain of 135 days over ten years is an average across everyone — some gain much more, many nothing. The relative risk of 0.88 means about 12% lower risk of death at the point of maximum difference.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.